Translational Research

A major focus of the Terry Fox Research Institute is translational research. Translation is often defined as research which moves discoveries made in the clinic to the laboratory and thence back to the bedside.  It is sometimes called “applied” research. This area of research holds great promise today for providing improved care and outcomes for cancer patients everywhere. Translational research is focused on speeding up the development and adoption of new treatments and technologies for the benefit of cancer patients and their families, the healthcare system and for the population at large. It covers the spectrum of cancer research from early detection and screening to diagnosis, treatment and monitoring of treatment. Translational research has been underfunded in the past partly because it is complex, involves many different disciplines and stakeholders, and is usually expensive to do. 

Please refer to the table below for the current portfolio of TFRI translational projects. Additional information for each can be found in the Canadian Research Information System (CRIS) database.

TFRI uses an iterative process to identify translational cancer research opportunities. The process is summarized in a TFRI Project Identification and Selection Process April 2012. Please note, application to TFRI for translational research projects is by invitation only.


List of Translational Cancer Research Projects


  Project  Start/End      Lead
Early Lung Cancer Detection (with CPAC) 2008-2015  Lam, S; Tsao, M
Sub-type management of Ovarian Cancer (with CPAC) 2009-2015 Mes-Masson, M; Huntsman, D; Provencher, D
FV-guided surgical trial for Oral Cancer control 2010-2015  Durham, S; Poh, C; Rosin, M
Stratifying and Targeting Pediatric Medulloblastoma through Genomics (with Genome Canada) 2011-2015 Taylor, M
Biomarker driven management of Prostate Cancer Phase II 2012-2016 Saad, F
Assignment to best available therapy for MDS/AML (Phase I) 2012-2014 Couban, S 
Therapeutic Targeting of Glioblastoma (with Alberta Cancer Foundation, Alberta Innovates, Genome Canada and others)
2012-2017  Cairncross, G
Pan-Canadian Colorectal Cancer Consortium (C4)
2012-2017 Batist, G; Gallinger, S

  Project  Start/End      Lead
TFRI/OICR Selective Therapy Program (with OICR) 2009-2013 Rottapel, R 
Multiple Myeloma (with ACB / CPAC) 2009-2013 Stewart, D; Bahlis, N
Development of OGX427 (Phase II study) 2010-2014 Chi, K
Retinoblastoma – International Phase III Trial 2010-2014 Chan, H
Nucleoside Analogs (leveraged with Univalor) 2011-2013 Guindon, Y
Shared Access Medicine: An Approach to Rare Tumours (SMART) 2012-2013 Tinker, A / McAlpine, J / Huntsman, D
3D Nuclear Telomeric Profiles at the Transition from MDS/AML 2012-2013 Mai, S
Selective Therapies Program Collaboration: Therapeutic Targets Validation in Ovarian Cancer 2012-2015 Mes-Masson, A-M / Rottapel, R
STP collaboration with the Centre for Drug Research and Development (CDRD) 2013-2015 Babcook, J / Rottapel, R
National Science Council (NSC) of Taiwan - TFRI Scientific Collaborations
  Project  Start/End      Lead
The Development of New Treatments and Biomarkers for Hepatocellular Carcinoma: from Woodchuck to Human 2013-2016 Bell, J / Chen, P-J
Development of 2-[18F]fluoro-2-deoxy-D-galactose as a new molecular imaging probe for hepatocellular carcinoma diagnosis 2013-2016 Benard, F / Kai-Yuan, T
Investigation of the Pathogenesis of ASXL1 mutation in acute myeloid leukemia 2013-2016 Humphries, Keith / Karsan, A / Tien, H-F / Kuo, Y-Y / Chou, W-C
Translational Research in Lung Cancer: from Molecular Markers / Targets to Therapeutic Applications 2013-2016 Lam, S / Lam, W / Yang, P-C / Yu, C-J